Mylan, the global pharmaceutical company, has named Bill Szablewski to the newly created role of head of capital markets, where he will manage both treasury and investor relations.
News of the appointment comes shortly after US authorities approved a merger of Mylan with Pfizer’s Upjohn business. Szablewski will hold the same position following the merger, when the combined company will be known as Viatris.
In the new role, Szablewski will report to Sanjeev Narula, who is currently CFO at Upjoin and has been named as the incoming finance chief at Viatris. Szablewski will also be a member of the merged company’s global finance leadership team.
He joins from Bristol Myers Squibb (BMS), where he served as assistant treasurer for capital markets and, prior to that, director of investor relations. He brings with him experience of working on BMS’ $74 bn acquisition of Celgene, which closed last year after also passing US regulatory approval.
Earlier in his career, Szablewski held a series of finance roles at Teva Pharmaceuticals, Verizon and BMS during a previous stint at the company.
‘We are thrilled to welcome Bill to the team and believe his leadership skills and vast expertise in capital markets and investor relations will be essential as we grow Viatris and develop as a company,’ says Robert Coury, Mylan’s executive chairman, in a statement.
‘I’m excited to be joining Viatris at this pivotal time as we prepare to launch a new kind of healthcare company focused on delivering high-quality medicines to patients in more than 165 countries,’ adds Szablewski in the statement.
‘I look forward to telling the Viatris story while building strong relationships across the investment community and financial markets globally.’
